Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome

Luca Castagna, Thomas Pagliardini, Stefania Bramanti, Jean Marc Schiano de Colella, Catalina Montes de Oca, Reda Bouabdallah, Jacopo Mariotti, Sabine Fürst, Angela Granata, Chiara De Philippis, Samia Harbi, Barbara Sarina, Faezeh Legrand, Valerio Maisano, Pierre Jean Weiller, Christian Chabannon, Carmelo Carlo-Stella, Armando Santoro, Didier Blaise, Raynier Devillier

Research output: Contribution to journalArticlepeer-review

Abstract

We report the outcome of 68 patients with advanced peripheral T-cell lymphoma receiving transplantation from haploidentical or from conventional donors. The 4-year OS, PFS, 2-year cumulative incidence of relapse and 2-year GRFS was 75%, 70%, 21%, and 51%, respectively. Survival was not affected by donor type. The 2-year NRM was 9%, lower after related or haploidentical donor (21% vs 0% vs 7%; p = 0.06). Grade 2-4 aGVHD cumulative incidence was significantly different after transplantation from haploidentical vs matched sibling vs unrelated donor, and (24% vs 35% vs 58%, p = 0.024). The familial donor cohort was compared to the unrelated cohort. Familial donor induced less grade 2-4 aGVHD, with a trend to less grade 3-4 aGVHD or moderate-severe cGVHD. The OS and PFS were not different, while the relapse risk and NRM were reduced. Allo-SCT is highly effective in T-cell lymphoma, with low NRM and low relapse rate. The incidence of aGVHD was lower after haploidentical transplantation. Related donor may challenge unrelated transplant reducing the risk of relapse and NRM.

Original languageEnglish
JournalBone Marrow Transplantation
DOIs
Publication statusE-pub ahead of print - Nov 15 2020

Fingerprint

Dive into the research topics of 'Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome'. Together they form a unique fingerprint.

Cite this